DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Pipeline Insight 2018 - ResearchAndMarkets.com

December 19, 2018

DUBLIN--(BUSINESS WIRE)--Dec 19, 2018--The “DP1 Receptor (Prostaglandin D2 receptor) Antagonist -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

‘DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Pipeline Insight, 2018’ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across DP1 Receptor (Prostaglandin D2 receptor) Antagonist development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

ClinicalNon-clinicalInactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. DP1 Receptor (Prostaglandin D2 receptor) Antagonist - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. DP1 Receptor (Prostaglandin D2 receptor) Antagonist Pipeline Products in Clinical Stages

6. DP1 Receptor (Prostaglandin D2 receptor) Antagonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies MentionedMerck Sharp & DohmeLigand PharmaceuticalsAtopix TherapeuticsAstraZeneca7TM PharmaShionogiNovartisBoehringer IngelheimActelion Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5w6w73/dp1_receptor?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181219005350/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/19/2018 07:29 AM/DISC: 12/19/2018 07:29 AM


Update hourly